Genetic markers of severe cutaneous adverse reactions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung , Jae-Woo | - |
dc.contributor.author | Kim, Jae-Yeol | - |
dc.contributor.author | Park, In-Won | - |
dc.contributor.author | Choi, Byoung-Whui | - |
dc.contributor.author | Kang, Hye-Ryun | - |
dc.date.available | 2019-01-22T12:38:24Z | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/818 | - |
dc.description.abstract | Adverse drug reactions can cause considerable discomfort. They can be lifethreat-ening in severe cases, requiring or prolonging hospitalization, impeding proper treatment, and increasing treatment costs considerably. Although the incidence of severe cutaneous adverse reactions (SCARs) is low, they can be serious, have permanent sequelae, or lead to death. A recent pharmacogenomic study confirmed that genetic factors can predispose an individual to SCARs. Genetic markers enable not only elucidation of the pathogenesis of SCARs, but also screening of susceptible subjects. The human leukocyte antigen (HLA) genotypes associated with SCARs include HLA-B*57:01 for abacavir (Caucasians), HLA-B*58:01 for allopurinol (Asians), HLA-B* 15:02 (Han Chinese) and HLA-A*31:01 (Europeans and Koreans) for carbamazepine, HLA-B*59:01 for methazolamide (Koreans and Japanese), and HLA-B*13:01 for dapsone (Asians). Therefore, prescreening genetic testing could prevent severe drug hypersensitivity reactions. Large-scale epidemiologic studies are required to demonstrate the usefulness and cost-effectiveness of screening tests because their efficacy is affected by the genetic differences among ethnicities. | - |
dc.format.extent | 9 | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.title | Genetic markers of severe cutaneous adverse reactions | - |
dc.type | Article | - |
dc.identifier.doi | 10.3904/kjim.2018.126 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.33, no.5, pp 867 - 875 | - |
dc.identifier.kciid | ART002376217 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000443196700004 | - |
dc.identifier.scopusid | 2-s2.0-85053295721 | - |
dc.citation.endPage | 875 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 867 | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 33 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Stevens-Johnson syndrome | - |
dc.subject.keywordAuthor | Drug hypersensitivity syndrome | - |
dc.subject.keywordAuthor | Pharmacogenetics | - |
dc.subject.keywordAuthor | HLA antigens | - |
dc.subject.keywordPlus | STEVENS-JOHNSON-SYNDROME | - |
dc.subject.keywordPlus | TOXIC EPIDERMAL NECROLYSIS | - |
dc.subject.keywordPlus | INDUCED HYPERSENSITIVITY REACTIONS | - |
dc.subject.keywordPlus | MAN CARRYING HLA-B-ASTERISK-59/01 | - |
dc.subject.keywordPlus | HLA-B REGION | - |
dc.subject.keywordPlus | DRUG-REACTIONS | - |
dc.subject.keywordPlus | KOREAN POPULATION | - |
dc.subject.keywordPlus | HAN CHINESE | - |
dc.subject.keywordPlus | THAI POPULATION | - |
dc.subject.keywordPlus | CARBAMAZEPINE | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.